阿达普特生物科技

最新新闻

• 评级变动
  Morgan Stanley Maintains Adaptive Biotechnologies(ADPT.US) With Hold Rating, Cuts Target Price to $13.54
  \u5e02\u573a\u8d44\u8baf · 2026/5/12
• 评级变动
  Guggenheim Maintains Adaptive Biotechnologies(ADPT.US) With Buy Rating, Raises Target Price to $22
  \u5e02\u573a\u8d44\u8baf · 2026/6/29
• 评级变动
  Piper Sandler Maintains Adaptive Biotechnologies(ADPT.US) With Buy Rating, Maintains Target Price $20
  \u5e02\u573a\u8d44\u8baf · 2026/5/12
• 评级变动
  Piper Sandler Maintains Adaptive Biotechnologies(ADPT.US) With Buy Rating, Maintains Target Price $27.5
  \u5e02\u573a\u8d44\u8baf · 2026/8/24
• 评级变动
  Analysts Offer Insights on Healthcare Companies: Neumora Therapeutics, Inc. (NMRA), Biomea Fusion (BMEA) and Adaptive Biotechnologies (ADPT)
  TipRanks · 2026/5/12
• 评级变动
  William Blair Maintains Adaptive Biotechnologies(ADPT.US) With Buy Rating
  \u5e02\u573a\u8d44\u8baf · 2026/6/17
• Adaptive Biotechnologies(ADPT.US) Officer Sells US$3.24 Million in Common Stock
  \u5e02\u573a\u8d44\u8baf · 2026/9/19
• BTIG Maintains Adaptive Biotechnologies(ADPT.US) With Buy Rating, Maintains Target Price $34
  \u5e02\u573a\u8d44\u8baf · 2026/9/22
• 评级变动
  Morgan Stanley Maintains Adaptive Biotechnologies(ADPT.US) With Hold Rating, Maintains Target Price $21
  \u5e02\u573a\u8d44\u8baf · 2026/2/10
• 评级变动
  A Quick Look at Today's Ratings for Adaptive Biotechnologies(ADPT.US), With a Forecast Between $20 to $22
  \u5e02\u573a\u8d44\u8baf · 2026/2/7
• 评级变动
  Piper Sandler Maintains Adaptive Biotechnologies(ADPT.US) With Buy Rating, Raises Target Price to $27.5
  \u5e02\u573a\u8d44\u8baf · 2026/8/4
• 评级变动
  A Quick Look at Today's Ratings for Adaptive Biotechnologies(ADPT.US), With a Forecast Between $25 to $28
  \u5e02\u573a\u8d44\u8baf · 2026/7/31
• Guggenheim Maintains Adaptive Biotechnologies(ADPT.US) With Buy Rating, Raises Target Price to $32
  \u5e02\u573a\u8d44\u8baf · 2026/10/1
• BTIG Maintains Adaptive Biotechnologies(ADPT.US) With Buy Rating, Raises Target Price to $34
  \u5e02\u573a\u8d44\u8baf · 2026/9/22
• Goldman Sachs Initiates Adaptive Biotechnologies(ADPT.US) With Buy Rating, Announces Target Price $35
  \u5e02\u573a\u8d44\u8baf · 2026/9/29
• 评级变动
  BTIG Maintains Adaptive Biotechnologies(ADPT.US) With Buy Rating, Raises Target Price to $24
  \u5e02\u573a\u8d44\u8baf · 2026/7/23
• 评级变动
  A Quick Look at Today's Ratings for Adaptive Biotechnologies(ADPT.US), With a Forecast Between $19 to $22
  \u5e02\u573a\u8d44\u8baf · 2026/5/6
• 评级变动
  TD Cowen Maintains Adaptive Biotechnologies(ADPT.US) With Buy Rating, Raises Target Price to $25
  \u5e02\u573a\u8d44\u8baf · 2026/7/15
• 评级变动
  Craig-Hallum Maintains Adaptive Biotechnologies(ADPT.US) With Buy Rating
  \u5e02\u573a\u8d44\u8baf · 2026/9/18
• 评级变动
  Analysts Offer Insights on Healthcare Companies: Evommune, Inc. (EVMN), RegenXBio (RGNX) and Adaptive Biotechnologies (ADPT)
  TipRanks · 2026/2/10

新闻标题为自动聚合内容，未经我们团队独立核实或编辑。